濮阳东方医院男科割包皮收费标准濮阳东方医院做人流咨询电话,濮阳东方妇科医院上班到几点,濮阳东方看妇科病专业,濮阳东方男科医院技术值得信赖,濮阳市东方医院评价很好,濮阳东方医院男科治疗早泄口碑好很不错,濮阳东方医院男科早泄效果

SYDNEY, Jan. 25 (Xinhua) -- Huawei Technologies, on Monday asked a U.S. District Court to prevent Motorola from illegally transferring Huawei's intellectual property (IP) to Nokia Siemens Networks ("NSN"), officials of Huawei told Xinhua in Sydney, Australia on Tuesday.As a leading player in providing next generation telecommunications network solutions, Huawei took this action as NSN seeks to complete its 1.2 billion U.S. dollars acquisition of Motorola's wireless network business.Since 2000, Huawei and Motorola have had a cooperative relationship in the radio access network and core network businesses, where Motorola has resold Huawei wireless network products to customers under the Motorola name. During this period, Motorola was provided with products and confidential Huawei IP developed by Huawei's team of more than 10,000 engineers.Since the July 2010 announcement by NSN of its purchase of Motorola's wireless network business, Huawei has tried to ensure that Motorola does not transfer this confidential information to NSN.According to officials of Huawei, Motorola's failure to adopt measures sufficient to ensure that Huawei's proprietary information remains confidential has compelled the company to file for the appropriate legal protection of its rights.The officials said Huawei respects the rights of intellectual property holders and is equally committed to the protection of its own innovations and intellectual property.Nearly half of Huawei's 100,000 plus employees are engaged in research and development and Huawei allocates an average of 10 percent of all revenues to R&D annually. By the end of 2010, Huawei had applied for 49,040 essential patents on a global basis.

MOSCOW, April 22 (Xinhua) -- The Russian Space Forces has re-established contact with a military satellite, Geo-IK-2, which went missing in February, local media reported Friday.According to a spokesman from the Defense Ministry, Interfax news agency said the Space Forces had already received telemetric information from the satellite and collection and analysis of the data were currently underway.After studying the information, the Defense Ministry would make a decision regarding the further use of the satellite, the spokesman said.A Rokot light-class carrier rocket carrying with the Geo-IK-2 satellite blasted off Feb. 1 from Russia's Plesetsk launching site, but placed the satellite in an incorrect orbit. After the launch, the Defense Ministry announced it had lost contact with the Geo-IK-2 and later abandoned the satellite.The Russian Space Forces then grounded launches of all Rokot light-class carrier rockets until the completion of an investigation into the failed launch.

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.

SAN FRANCISCO, May 25 (Xinhua) -- Micro-blogging service Twitter on Wednesday confirmed that it has bought TweetDeck, a London-based startup that develops application to help people organize information posted on Twitter."Today, we're pleased to announce that the TweetDeck team has joined Twitter," Dick Costolo, Twitter's chief executive officer (CEO), said in a blog post."This acquisition is an important step forward for us. TweetDeck provides brands, publishers, marketers and others with a powerful platform to track all the real-time conversations they care about," he added.Founded in 2008, TweetDeck now has a team of 15 and offers a real-time application that allows users to monitor abundance of information from social media services including Twitter in a single concise view."Change may well be inevitable, but we remain the same team, staying in London, with the same focus and products, and now with the support and resources to allow us to grow and take on even bigger challenges," Iain Dodsworth, founder and CEO of TweetDeck, noted in a separate blog post.The deal is a defensive move for Twitter aimed at preventing TweetDeck from being purchased by rivals, some analysts said.Financial terms of the transaction were not disclosed, but technology blog site TechCrunch and other U.S. media reported that Twitter paid 40 million to 50 million U.S. dollars.

BEIJING, May 19 (Xinhuanet) -- LinkedIn said Wednesday that its stock will debut at 45 U.S. dollars per share, a higher price than the company was expecting even earlier this week, media reports said.The first major U.S. social networking firm to go public, LinkedIn jacked up its initial public offering (IPO) share price for 7.84 million shares to 45 dollars just a week after it first set a target of 32-35 dollars per share.It minted LinkedIn with a market value of more than 4 billion dollars, the highest for a U.S. Internet company taking its first bow on Wall Street since Google Inc. went public nearly seven years ago.The sale could bring in more than 354 million dollars. The company's shares are expected to begin trading on the New York Stock Exchange on Thursday under the symbol "LNKD".LinkedIn has more than 100 million members in over 200 countries and territories. In 2010, the company made 15 million dollars in profit on 243 million dollars in revenue, according to its SEC filing.LinkedIn's biggest shareholder is its founder and chairman, Reid Hoffman, who owns more than 21 percent of the company.